Oncology

News

US and UK flags meet on a diagonal, with grey border line

AbbVie joins BMS in taking a hard line on UK drug pricing

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.

Oncology

News and advice from an investor-CEO, with Milenko Cicmil

pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.

News

Genmab agrees $8bn takeover of cancer biotech Merus

Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.

News

Lilly brings second oral SERD to market for breast cancer

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

BMS eyes filings for myeloma 'celmod' iberdomide

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.

Oncology

The cancer community must seize the opportunity of the Natio...

With the government’s National Cancer Plan due for publication this autumn, we have an opportunity to fundamentally improve how we deliver innovation.

AbbVie joins BMS in taking a hard line on UK drug pricing

News and advice from an investor-CEO, with Milenko Cicmil

Genmab agrees $8bn takeover of cancer biotech Merus

Lilly brings second oral SERD to market for breast cancer

BMS eyes filings for myeloma 'celmod' iberdomide

The cancer community must seize the opportunity of the Natio...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks